The new test allows to recognize traumatic brain injury within 10 minutes on the basis of a single drop of blood - informs the magazine "PLOS ONE".
MEPs passed an amendment to the law on the treatment of high-pressure drugs like drugs. The new regulations will apply from November 1, 2018.
Introduction of an Internet Patient Account (IKP) - assumes the amendment of the Act adopted by the Sejm. The regulations provide for the possibility of mail order sale of prescription drugs to people with disabilities. In addition, under the act, contracts on AOS are to be extended until the end of 2019.
In January 2018, a new drug was registered in Europe - definilumumab, which gives a chance to increase the individualization of therapy for patients with relapsing-remitting multiple sclerosis. It is also the first ever drug that can be successfully used in the primary progressive form of MS.
Hundreds of thousands of patients took medications for hypertension that may have been defective. Almost all of their producers were supplying one factory in China.
Already in December, the residents of Great Britain will be able to make an appointment to visit their doctor and order a prescription via cell phone.
American scientists are close to developing a new drug that will help in the treatment of disorders related to alcohol abuse.
Every year, over 30,000 die in Poland due to diabetes and its complications. people. That is why a long-term strategy is needed to combat this disease - experts at the meeting of parliamentary teams on diabetes and primary care emphasized on Wednesday.
Thanks to the discovery of a new small-cell lung cancer (SCLC), it will be possible to better adapt the treatment to a specific patient - informs Genes & Development.
Influenza vaccines for people over 65, new drugs for schizophrenia, hepatitis C and a new therapy for the treatment of primary immune deficiencies in children include a list of reimbursed drugs that comes into force on July 1.
The administrator of the personal data provided above is lapharma.info S.A. with headquarters in Toruń, ul. Szosa Bydgoska 58. In the event of consent, your personal data will be processed by lapharma.info S.A. in order to provide the newsletter service (including, among others, commercial and marketing information about the products and services of the own data controller and entities cooperating with it). You have the right to access your data and correct it. Providing an e-mail address is voluntary, but necessary to use the newsletter.
I declare that I have read the Regulations and accept its provisions.
I agree to the processing of my personal data (ie e-mail address) by lapharma.info S.A.with headquarters in Toruń, ul. Szosa Bydgoska 58 to send a newsletter (containing, among others, commercial and marketing information about the products and services of the own data controller and entities cooperating with it), in accordance with the Personal Data Protection Act of August 29, 1997 (Dz.U. 2016, item 922, as amended).
I agree to receive a newsletter containing commercial information within the meaning of the Act of 18 July 2002 on the provision of electronic services (Journal of Laws of 2016, item 1030, as amended) to the e-mail address provided above, sent by lapharma.info SA on their own behalf and on behalf of cooperating entities.
I agree to use S.A. by lapharma.info. with headquarters in Toruń, ul. Szosa Bydgoska 58 telecommunications terminal equipment and automatic calling systems for direct marketing purposes in accordance with art. 172 of the Act of 16 July 2004 Telecommunications Law (consolidated text: Journal of Laws of 2014, item 243, as amended).
The administrator of personal data is lapharma.info S.A. with headquarters in Toruń, ul. Szosa Bydgoska 58. Personal data will be processed in terms of access and use of the Portal, as well as for commercial, marketing, educational and statistical purposes and will not be disclosed to other recipients, in accordance with the Act on the Protection of Personal Data of 29 August 1997 (ie Dz U. 2015 item 2135, as amended).Portal Users have the right to access their data and correct them.Providing personal data is voluntary, but necessary to achieve the above objectives.
I consent to the processing of my personal data provided by me during the registration in the field of access and use of the Portal.
I agree to the processing of my personal data provided in the above form for marketing purposes of my own products and services and cooperating entities.
I consent to the processing of my personal data provided in the above form for educational purposes.
I consent to the processing of my personal data provided in the above form for statistical purposes.
I agree to receive commercial information by email at the e-mail address provided above, sent by lapharma.info S.A. on behalf of and on behalf of cooperating entities, in accordance with the Electronic Services Provision Act of July 18, 2002 (consolidated text: Journal of Laws of 2013, item 1422, as of 2015, item 1844).
I agree to use automatic calling systems for direct marketing purposes, in accordance with the Telecommunications Act of 16 July 2004 (Journal of Laws of 2014, item 243, 827, 1198, from 2015 item 1069) .
I declare that I have read itRegulations of the Pharmaceutical and Medical Portal and I accept its provisions.